全文获取类型
收费全文 | 2517篇 |
免费 | 132篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 122篇 |
妇产科学 | 108篇 |
基础医学 | 225篇 |
口腔科学 | 70篇 |
临床医学 | 194篇 |
内科学 | 568篇 |
皮肤病学 | 35篇 |
神经病学 | 107篇 |
特种医学 | 499篇 |
外科学 | 376篇 |
综合类 | 60篇 |
预防医学 | 79篇 |
眼科学 | 27篇 |
药学 | 106篇 |
1篇 | |
中国医学 | 16篇 |
肿瘤学 | 49篇 |
出版年
2023年 | 12篇 |
2022年 | 22篇 |
2021年 | 55篇 |
2020年 | 24篇 |
2019年 | 31篇 |
2018年 | 53篇 |
2017年 | 41篇 |
2016年 | 46篇 |
2015年 | 52篇 |
2014年 | 94篇 |
2013年 | 105篇 |
2012年 | 98篇 |
2011年 | 100篇 |
2010年 | 91篇 |
2009年 | 91篇 |
2008年 | 85篇 |
2007年 | 118篇 |
2006年 | 113篇 |
2005年 | 98篇 |
2004年 | 73篇 |
2003年 | 51篇 |
2002年 | 59篇 |
2001年 | 28篇 |
2000年 | 18篇 |
1999年 | 32篇 |
1998年 | 86篇 |
1997年 | 88篇 |
1996年 | 84篇 |
1995年 | 66篇 |
1994年 | 40篇 |
1993年 | 61篇 |
1992年 | 9篇 |
1991年 | 17篇 |
1990年 | 31篇 |
1989年 | 64篇 |
1988年 | 46篇 |
1987年 | 55篇 |
1986年 | 59篇 |
1985年 | 71篇 |
1984年 | 40篇 |
1983年 | 40篇 |
1982年 | 36篇 |
1981年 | 35篇 |
1980年 | 39篇 |
1979年 | 11篇 |
1978年 | 23篇 |
1977年 | 26篇 |
1976年 | 21篇 |
1975年 | 21篇 |
1914年 | 1篇 |
排序方式: 共有2664条查询结果,搜索用时 15 毫秒
991.
目的:研究OCT3检测青光眼视网膜神经纤维层厚度与Humphrey750型视野计检测视野缺损的相关性。方法:维吾尔族青光眼47例79眼,汉族青光眼对照组21例38眼,维吾尔族正常对照组15例30眼,分别对各组进行OCT3和视野检测,比较各组指标差异,并进行视网膜神经纤维层厚度与视野相关性分析以及维族青光眼组分层分析。结果:维族青光眼组与维族正常组间的比较结果为两组的OCT1∶00,11∶00及上象限、全自动视野的MD和PSD差异具有极显著性(P<0.01),OCT6∶00,7∶00,12∶00和下象限差异具有显著性(P<0.05),维族青光眼组与汉族青光眼组间的OCT参数差异没有显著性。维族青光眼组OCT指标与视野指标相关且随着青光眼分期相关性加强。结论:OCT在青光眼的诊断中有较好的诊断价值,OCT在青光眼的视网膜神经纤维层厚度检测与视野相关,OCT检测能够验证视野的检测,为青光眼的诊断提供了量化标准。 相似文献
992.
目的:用诊断试验的方法,分析原发性青光眼视野与视网膜神经纤维层厚度改变,进一步验证倍频视野技术(frequency doubling technology,FDT)与光学相干断层扫描(optical coherence tomography,OCT)的诊断效能,比较两者在临床应用中的诊断价值。方法:设计一个前瞻性诊断试验,分别应用OCT和FDT对83例162只青光眼及疑似青光眼进行检测,根据检测结果得出各诊断试验的诊断指标,并对两者进行比较和联合试验。得出两者的验前和验后概率。结果:两者的灵敏度和特异度比较,均有P>0.05。两者的联合灵敏度为88.4%,诊断效能较单纯OCT提高了11.84%,较FDT提高了18.09%。联合特异度为84.42%,诊断效能较单纯OCT提高了29.32%,较FDT提高了19.11%。两者的验前概率为39.51%,验后概率分别为52.83%和57.08%。结论:OCT与FDT在诊断原发性青光眼的应用中有较好的诊断价值,且两者诊断效能的差异不大,两者联合可以大大提高其诊断价值。在临床应用中,还不能单纯依靠OCT或FDT的诊断结果来判定原发性青光眼,对原发性青光眼的诊断尚需进一步检查。 相似文献
993.
994.
SD Silberstein J Schoenen H Göbel HC Diener AH Elkind JA Klapper & RA Howard 《Cephalalgia : an international journal of headache》2009,29(S2):17-27
Tonabersat is a novel benzopyran derivative that blocks the cortical spreading depression proposed to be associated with migraine attacks. The ability of single oral doses of 15, 25, 40 and 80 mg of tonabersat to relieve the symptoms of moderate to severe migraine was evaluated in 859 migraineurs enrolled in two dose-ranging, double-blind, randomized, placebo-controlled, parallel-group trials, one international and the other North American. In the international study, significantly more patients given tonabersat than given placebo experienced relief of headache pain at 2 h (15 mg, 36.8%; 40 mg, 40.7%), the principal efficacy variable, and at 4 h (40 mg, 63.0%) and complete abolition of headache at 4 h (40 mg, 34.3%). None of the primary or secondary efficacy variables indicated significant differences between tonabersat and placebo in the North American study. Tonabersat was generally well tolerated, with dizziness and nausea the most common side-effects. Serious adverse events were uncommon, and no patient withdrew from either study because of adverse events. These results suggest a possible interplay between tonabersat pharmacokinetics (the relatively long time required to reach maximum plasma concentrations) and patient characteristics (previous triptan exposure) in the management of acute migraine attacks. Based on the pharmacokinetics and actions on cortical spreading depression, tonabersat may have potential value in migraine prophylaxis. 相似文献
995.
996.
Lipomas are the most common benign tumours that originate from adipose tissue and can develop in any anatomical location where the adipose tissue layer is present in the body. Penile lipoma cases are very rare in the literature. Our case is a 21‐year‐old male patient who underwent TIPU operation 8 years ago due to distal hypospadias. One year after the operation, a palpable swelling at the midline of the ventral portion of the penis occurred and this lesion grew over time. In this case report, we present a patient with lipoma that was developed in the surgical area 1 year after hypospadias surgery. To the best of our knowledge, this is one of the first cases of penil lipoma related to hypospadias procedure. 相似文献
997.
Efficacy and safety of fixed‐dose combination therapy,alogliptin plus metformin,in Asian patients with type 2 diabetes: A phase 3 trial 下载免费PDF全文
Linong Ji MD Ling Li MD Jian Kuang MD Tao Yang MD Dong‐Jun Kim MD PhD Azidah A. Kadir MD Chien‐Ning Huang MD Douglas Lee MD 《Diabetes, obesity & metabolism》2017,19(5):754-758
This study evaluated the efficacy and safety of 26 weeks of twice‐daily (BID) alogliptin + metformin fixed‐dose combination (FDC) therapy in Asian patients with type 2 diabetes. Patients aged 18 to 75 years with hemoglobin A1c (HbA1c) of 7.5% to 10.0% after ≥2 months of diet and exercise and a 4‐week placebo run‐in were enrolled. Eligible patients were randomized (1:1:1:1) to placebo, alogliptin 12.5 mg BID, metformin 500 mg BID or alogliptin 12.5 mg plus metformin 500 mg FDC BID. The primary endpoint was change in HbA1c from baseline to end of treatment (Week 26). In total, 647 patients were randomized. The least‐squares mean change in HbA1c from baseline to Week 26 was ?0.19% with placebo, ?0.86% with alogliptin, ?1.04% with metformin and ?1.53% with alogliptin + metformin FDC. Alogliptin + metformin FDC was significantly more effective ( P < .0001) in lowering HbA1c than either alogliptin or metformin alone. The safety profile of alogliptin + metformin FDC was similar to that of the individual components alogliptin and metformin. The study demonstrated that treatment with alogliptin + metformin FDC BID resulted in better glycaemic control than either monotherapy and was well tolerated in Asian patients with type 2 diabetes. 相似文献
998.
999.
Serkan Yarimoglu Ibrahim Halil Bozkurt Ozgu Aydogdu Tarik Yonguc Ertugrul Sefik Yusuf Kadir Topcu Tansu Degirmenci 《The Kaohsiung journal of medical sciences》2017,33(10):516-522
The aim of this study was validation and comparison of stone scoring systems (S.T.O.N.E, GUY, CROES, S-ReSC) used to predict postoperative stone-free status and complications after percutaneous nephrolithotomy (PCNL) for staghorn stones. A total of 160 patients who had staghorn renal stones and underwent PCNL between January 2012 and August 2015 were included in the current retrospective study. Guy, S.T.O.N.E., S-ReSC (Seoul National University Renal Stone Complexity) and CROES (Clinical Research Office of the Endourological Society) nephrolithometry scores were calculated for each patient, and their potential association with stone-free status, operative and fluoroscopy time, and length of hospital stay (LOS) were evaluated. Postoperative complications were graded according to the modified Clavien classification, and the correlation of scoring systems with postoperative complications was also investigated. The mean CROES, S.T.O.N.E, Guy and S-ReSC scores were 143.5 ± 33.6, 9.7 ± 1.6, 3.5 ± 0.5 and 6.2 ± 2.0 respectively. The overall stone-free rate was 59%. All scoring systems were significantly correlated with stone-free status in univariate analysis. However, Guy and S-ReSC scores were the only significant independent predictor in multivariate analysis. And all four nomograms failed to predict complication rates. Current study demonstrated that Guy and S-ReSC scoring systems could effectively predict postoperative stone-free status for staghorn stones. However all four scoring systems failed to predict complication rates. 相似文献
1000.